Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)

Introduction and objectivesPatients (pts) with metastatic urothelial carcinoma (mUC) gain substantial benefit from immunotherapy exposure. If they do not experience disease progression after 4-6 cycles of first-line platinum-based chemotherapy (PBC), they may benefit from immunotherapy as maintenanc...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Francesca Zacchi, Anna Sordo, Irene Torresan, Clara Lorenzi, Ester Tasselli, Sarah Pafumi, Silvia Palmerio, Emilia Durante, Nicola Inzerilli, Mattia Pellicciari, Davide Pastorelli, Michele Milella, Giulia Lorenzoni, Sara Merler, Andrea Zivi
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2025-02-01
Saila:	Frontiers in Oncology
Gaiak:	urothelial cancer immunotherapy avelumab pembrolizumab survival
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1532421/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!